Related Experiment Video
Updated: Jul 6, 2025
14:24
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
11.7K
New Concepts in Cardio-Oncology
Paola Zagami1,2, Eleonora Nicolò3,4, Chiara Corti3,4
1Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy. paola.zagami@ieo.it.
Cancer Treatment and Research
|January 4, 2024
Summary
Breast cancer treatments can cause heart problems. Early detection and a team approach by oncologists and cardiologists improve cardiovascular care for cancer patients.
Area of Science:
- Cardio-oncology
- Oncology
- Cardiology
Background:
- Cancer and cardiovascular disease are leading causes of death globally.
- Breast cancer (BC) treatments improve survival but risk cardiovascular adverse events (CV-AEs).
- Cardiotoxicity from cancer therapies can manifest in various cardiovascular conditions.
Purpose of the Study:
- To review cardiotoxic manifestations of BC treatments.
- To discuss prevention, monitoring, and management of CV-AEs.
- To highlight the importance of a multidisciplinary approach in cardio-oncology.
Main Methods:
- Literature review of cardiotoxicity associated with BC therapies.
- Analysis of cardiotoxic effects from chemotherapy, anti-HER2 agents, CDK4/6 inhibitors, PARP inhibitors, antiangiogenic drugs, and immunotherapy.
- Focus on clinical manifestations, early detection, and management strategies.
Main Results:
- Various cancer therapies pose risks for cardiovascular adverse events.
- Early detection of CV-AEs is crucial for effective treatment and better outcomes.
- A collaborative approach between oncologists and cardiologists is essential.
Conclusions:
- Cardio-oncology is vital for managing cardiotoxicity in BC patients.
- Comprehensive monitoring and timely intervention can mitigate CV-AEs.
- Understanding drug-specific cardiotoxicity aids in personalized patient care.
Related Concept Videos
01:29Pathophysiology of Cardiac Performance
671
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
671
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
160
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
160
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K